Joerg Moeller via Getty
Bayer hands over a big drug R&D operation to CRO amid an ongoing restructuring effort
Bayer’s 400-strong small molecule R&D team is being carved out and handed to a CRO, where they’ll continue to work for Bayer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.